Abstract
Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during phase III trials, have been shown to reduce relapse rates in relapsing-remitting multiple sclerosis (RRMS) as detected by magnetic resonance imaging (MRI). However, the longterm effects of DMDs on MS progression are not very clear; therefore, the aim of this paper is to evaluate the evidence available of the long-term effects of DMDs on reducing the progression of multiple sclerosis. A number of open-label, prospective extensions that followed a cohort of patients enrolled in double-blind, placebo-controlled trials were examined. Methodological difficulties faced in designing a trial of extended duration were hard to overcome, however, and long-term, open-label extensions of interferon and glatiramer acetate failed to show significant beneficial effects in delaying disability progression, questioning the cost-effectiveness of these therapies in the long-term.
Keywords: Multiple sclerosis, demylinating, disease-modifying agents, glatiramer acetate, interferon, relapse
CNS & Neurological Disorders - Drug Targets
Title: Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
Volume: 8 Issue: 6
Author(s): Oleksandra Katrych, Tessa M. Simone, Shara Azad and Shaker A. Mousa
Affiliation:
Keywords: Multiple sclerosis, demylinating, disease-modifying agents, glatiramer acetate, interferon, relapse
Abstract: Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during phase III trials, have been shown to reduce relapse rates in relapsing-remitting multiple sclerosis (RRMS) as detected by magnetic resonance imaging (MRI). However, the longterm effects of DMDs on MS progression are not very clear; therefore, the aim of this paper is to evaluate the evidence available of the long-term effects of DMDs on reducing the progression of multiple sclerosis. A number of open-label, prospective extensions that followed a cohort of patients enrolled in double-blind, placebo-controlled trials were examined. Methodological difficulties faced in designing a trial of extended duration were hard to overcome, however, and long-term, open-label extensions of interferon and glatiramer acetate failed to show significant beneficial effects in delaying disability progression, questioning the cost-effectiveness of these therapies in the long-term.
Export Options
About this article
Cite this article as:
Katrych Oleksandra, Simone M. Tessa, Azad Shara and Mousa A. Shaker, Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes, CNS & Neurological Disorders - Drug Targets 2009; 8 (6) . https://dx.doi.org/10.2174/187152709789824598
DOI https://dx.doi.org/10.2174/187152709789824598 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Advances in Electrospinning of Nanofibers and their Biomedical Applications
Current Tissue Engineering (Discontinued) Coronary Microvascular Dysfunction and Heart Failure with Preserved Ejection Fraction - implications for Chronic Inflammatory Mechanisms
Current Cardiology Reviews COX-Inhibiting Nitric Oxide Donors (CINODs): Potential Benefits on Cardiovascular and Renal Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Androgen Receptor Antagonists in the Treatment of Prostate Cancer
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Tobacco Smoking and Association between Betel Nut Chewing and Metabolic Abnormalities Among Military Males: The CHIEF Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors
CNS & Neurological Disorders - Drug Targets Platelet Concentrates for Topical Use: Bedside Device and Blood Transfusion Technology. Quality and Versatility
Current Pharmaceutical Biotechnology Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine A 2015 Update on The Natural History and Diagnosis of Nicotine Addiction
Current Pediatric Reviews Chronic Heart Failure and Exercise Intolerance: The Hemodynamic Paradox
Current Cardiology Reviews